Leadership
Aegerion’s management team, board and scientific advisors are leaders in their respective fields focused on research, development, commercialization and treatment of debilitating and fatal orphan diseases. Everyone at Aegerion does their part to advance lomitapide, our life-altering therapy to treat severe lipid disorders, into and through the pipeline. Whether we're designing or conducting clinical trials, collaborating with business partners, establishing a commercialization organization or raising capital, we are all committed to delivering our products to people afflicted with rare and often fatal diseases who need them.
Marc Beer
Chief Executive Officer
 Marc Beer is the Chief Executive Officer of Aegerion (AEGR). Aegerion Pharmaceuticals is focused on the commercialization of life-altering therapy for debilitating and fatal orphan diseases. Marc took Aegerion public in October, 2010. Marc brings over 20 years of development and commercialization experience in biotechnology, pharmaceuticals and diagnostics. In April 2000, Marc became the founding CEO of Viacell (VIAC), a biotechnology company specializing in the collection, preservation and development of umbilical cord blood stem cells, and over a period of seven years led the company from its inception to a rapidly growing and robust commercial organization. Under Marc's leadership, the company grew to more than 300 employees, went public in 2005 and was ultimately acquired in 2007 by PerkinElmer (PKI). Prior to founding Viacell, Marc held various positions within Genzyme (GENZ), most recently as Vice President of Global Marketing where he was responsible for the commercial launch of several products addressing orphan disease populations on a global scale. Prior to Genzyme, he held a variety of sales and marketing roles in the pharmaceutical and diagnostic divisions of Abbott Laboratories (ABT). He also was a former member of the Mass Life Science Board of the Commonwealth of Massachusetts. Marc serves on the Biotechnology Industry Organization (BIO) Emerging Companies Section Governing Board as well as on the board of directors of Good Start Genetics, Inc. where he is Chairman; Seaside Therapeutics, Inc. and ERYtech Pharma. Marc holds a B.S. from Miami University (Ohio).
Mark Fitzpatrick
Chief Financial Officer
 Mark Fitzpatrick was appointed Chief Financial Officer in April of 2011. He brings over 15 years of financial management experience in both public and private companies. He was most recently Vice President, Chief Financial Officer and Assistant Secretary at Proteon Therapeutics, Inc. Prior to his role at Proteon, Mr. Fitzpatrick was Vice President and Chief Financial Officer, Treasurer and Assistant Secretary with RenaMed Biologics, Inc. He also held CFO positions with Dynogen Pharmaceuticals, WorldStreet Corporation and Diacrin. He previously was a senior auditor with Arthur Andersen & Co. Mr. Fitzpatrick earned a Certified Public Accountant certificate in the Commonwealth of Massachusetts in 1987, and holds a B.S. in Accounting from Boston College.
Anne Marie Cook
Senior Vice President, General Counsel and Secretary
 Anne Marie Cook was appointed Senior Vice President, General Counsel and Secretary in December 2011. Ms. Cook was most recently a partner with Boston-based law firm Choate Hall & Stewart LLP (Choate). There she represented life science companies in structuring and negotiating strategic transactions such as joint ventures, collaborations, mergers and acquisitions and intellectual property licenses. She also provided general legal support in connection with the research, development and commercialization of pharmaceutical products. Prior to joining Choate, Ms. Cook was Senior Vice President, Business & Corporate Development, General Counsel at ViaCell, Inc. Prior to that, she was Vice President, Chief Corporate Counsel, at Biogen Idec Inc.
Martha Carter
Chief Regulatory Officer
 Martha Carter was appointed Chief Regulatory Officer of Aegerion in February 2011, bringing over 30 years of regulatory affairs experience in prescription and over-the-counter drugs, biologics, biotechnology products, and medical devices. Prior to joining Aegerion, Martha was Senior Vice President and Chief Regulatory Officer at Proteon Therapeutics, Inc. where she was responsible for the company's worldwide regulatory and quality functions. Prior to this role, she was Senior Vice President, Regulatory Affairs, for Trine Pharmaceuticals. Prior to that, Martha was Vice President, Regulatory Affairs for GelTex Pharmaceuticals, Inc. In this role, she led the company's regulatory and quality control functions for both commercial and investigational drug products. Martha is a Fellow of the Regulatory Affairs Professionals Society, and is a past President and Chairman of the Board. She is also a former member of the Editorial Advisory Board for Applied Clinical Trials and BioPharm. Martha holds a B.A. in Biology from Northeastern University.
Mark Sumeray, MD, MS, FRCS
Chief Medical Officer
 Dr. Sumeray brings development, regulatory and medical affairs experience with cardiovascular drugs such as Plavix®, apixaban, Avapro®/Avalide®, and Angiomax® to Aegerion. Dr. Sumeray was most recently Vice President Cardiovascular/Metabolics U.S. Medical, at Bristol-Myers Squibb. In this role, he was responsible for U.S. medical strategy for the CV and metabolics medical strategy teams, including implementation across the medical affairs function working collaboratively with marketing, sales, global clinical research and health outcomes. Prior to this role, Dr. Sumeray held several positions of increasing responsibility within The Medicines Company, including Vice President and Business Unit Co-Leader, Vice President Medical Business Development, and Vice President Clinical Development and Head of Medical Science. Prior to that, Dr. Sumeray was worldwide Vice President of Clinical Development for the Ethicon Franchise of Johnson & Johnson.
David Scheer
Chairman of the Board, Aegerion Pharmaceuticals
David Scheer is President of Scheer & Company, Inc., a firm founded in 1981, with activities in venture capital, corporate strategy, and transactional advisory services focused on the life sciences. Mr. Scheer was involved in the founding and had been a member of the Boards of Directors of ViroPharma, Inc.(NASDAQ, “VPHM”), OraPharma, Inc. (acquired by Johnson & Johnson in 2003), and Esperion Therapeutics, Inc. (of which he was Chairman, acquired by Pfizer in 2004). His current board relationships include Achillion Pharmaceuticals, Inc. (of which he is Chairman, NASDAQ, “ACHN”), Tengion, Inc. (of which he is Chairman, NASDAQ, “TNGN”), Aegerion Pharmaceuticals, Inc. (of which he is Chairman), Optherion, Inc. (of which he is Chairman), and Axerion Therapeutics, Inc. (of which he is Chairman).. From 1991 through 1999, he was affiliated with the health care investing team at Oak Investment Partners. Mr. Scheer has also led or played a significant role in a series of transactions involving corporate alliances, licensing arrangements, divestments, acquisitions and mergers in the life sciences. He has served as a member of the Leadership Council of the Harvard School of Public Health, and as a member of the Advisory Committee to the Harvard Malaria Initiative. He has helped to launch, and served as Chair of the Executive Committee for “The Unfinished Agenda in Infectious Diseases”, an initiative at the Harvard School of Public Health focusing on the neglected diseases. He has also been a member of the Global Advisory Council for AIDS@30, an initiative at Harvard, and the Chair of the Strategic Advisory Committee for the Global Task Force for Expanding Cancer Care and Control in the Developing World, another Harvard-affiliated initiative. He has also been a member of the Board of Trustees, and most recently Vice-Chair for the Long Wharf Theatre, in New Haven, CT. In 2007, he was awarded the Atlas Award for Venture Capital from the Connecticut Union for Research Excellence (CURE, of which he also serves as a member of the Board), and in 2009, he received the Venture Capital Leadership Award from the Connecticut Venture Group. He received his A.B. cum laude from Harvard College, and an M.S. from Yale University.
Marc Beer
CEO, Aegerion Pharmaceuticals
Marc Beer was appointed Chief Executive Officer of Aegerion on August 2010 bringing over 20 years of development and commercialization experience in biotechnology, pharmaceuticals and diagnostics. In April 2000 Marc became the founding CEO of Viacell (VIAC), a biotechnology company specializing in the collection and preservation of umbilical cord blood stem cells, and over a period of 7 years led the company from its inception to a rapidly growing and robust commercial organization. Under Marc's leadership, the company grew to more than 300 employees, went public in 2005 and was ultimately acquired in 2007 by PerkinElmer (PKI). Prior to founding Viacell, Marc held various positions within Genzyme (GENZ), most recently as Vice President of Global Marketing where he was responsible for the commercial launch of several products addressing orphan disease populations on a global scale. Prior to Genzyme, he held a variety of sales and marketing roles in the pharmaceutical and diagnostic divisions of Abbott Laboratories (ABT). He also was a former member of the Mass Life Science Board of the Commonwealth of Massachusetts. Marc serves on the Biotechnology Industry Organization (BIO) Emerging Companies Section Governing Board as well as on the board of directors of Good Start Genetics, Inc. where he is Chairman; Seaside Therapeutics, Inc. and ERYtech Pharma. Marc holds a B.S. from Miami University (Ohio).
Dr. Sol J. Barer, Ph.D.
Chairman, Celgene
Dr. Barer is the Chairman of Celgene. He previously served as Chairman and Chief Executive Officer from May 2006 until June 2010, when he was appointed Executive Chairman and transitioned to his current position in January 2011. Prior to that, he held several positions within Celgene, including President and Chief Operating Officer. Dr. Barer joined the Celanese Research Company in 1974 and formed the biotechnology group that was subsequently spun out to form Celgene. Dr. Barer also currently serves on the Board of Directors of Amicus Therapeutics, the Board of Directors of ContraFect, is Chairman of the Board of Trustees for BioNJ and Chairs the University of Medicine and Dentistry of New Jersey Advisory Committee. Dr. Barer received a Ph.D. in Organic Chemistry from Rutgers University and a B.S. from Brooklyn College.
Dr. Antonio M. Gotto Jr., M.D., D.Phil
Weill Medical College of Cornell University
Dr. Gotto has served as a member of the board since January 2005. Dr. Gotto has been Dean of the Weill Medical College of Cornell University and Provost for Medical Affairs, Cornell University, since January 1997. He was Chairman and Professor of the Department of Medicine at Baylor College of Medicine and Methodist Hospital from 1977 through 1996 and former J. S. Abercrombie Chair, Atherosclerosis and Lipoprotein Research from 1976 to 1996. He is Past President, International Atherosclerosis Society, Past President, American Heart Association, a member of the Institute of Medicine of the National Academy of Sciences and a Fellow of the American Academy of Arts and Sciences
Sandford ("Sandy") D. Smith
Sandy Smith joined Aegerion's Board of Directors as a member of the Audit Committee in January 2012. Mr. Smith was most recently Executive Vice President and President International Group for Genzyme Corporation (Genzyme), where he was a member of the company's Executive Committee. As President of the International Group, Mr. Smith grew Genzyme's offshore revenue to 65 percent of Genzyme's nearly $5 billion revenues. During his tenure, Mr. Smith was responsible for the successful global launch of 12 new products in various therapeutic categories, including rare diseases. Mr. Smith joined Genzyme in 1996, and served as Vice President and General Manager of Genzyme International and President of Genzyme Specialty Therapeutics before being named to his most recent position. Following Sanofi's acquisition of Genzyme in April of 2011, Mr. Smith was responsible for the integration of Genzyme's international business into the Sanofi global organization. Prior to joining Genzyme, Mr. Smith was President and Chief Executive Officer at Repligen Corporation. Under his leadership, Repligen completed several secondary stock offerings, raising more than $100 million, and established important partnerships with Merck, Eli Lilly, Gillette, and Centocor/Johnson & Johnson. He also held several international leadership positions within Bristol Myers Squibb. Mr. Smith has served as a Director on a number of boards of both public and private healthcare companies, including Ariad Pharmaceuticals, NVenta and BioBehavioral Diagnostics. He currently is a member of the Board of Trustees of Brigham and Women’s Hospital in Boston.
Paul G. Thomas
Roka Bioscience
Mr. Thomas is the Founder and CEO of Roka Bioscience, a private company developing and marketing molecular assays and instrument systems for microbiological testing. During his tenure at Roka, he led the spinout of Gen-Probe's technology assets into a new independent company with financial sponsorship from private equity firms including Orbimed Advisors, New Enterprise Associates and TPG Biotech. Prior to founding Roka Bioscience, Thomas was President, CEO and Chairman of LifeCell Corporation, a regenerative medicine company which was acquired by Kinetic Concepts in a $1.8 billion cash transaction in May 2008. Prior to that, Thomas held several positions within OHMEDA PPD (Now Baxter PPD), most recently President and Chief Operating Officer. He earned a Master of Business Administration from Columbia University Business School and a Bachelor of Arts in Chemistry from St. Michael's College.
Daniel J. Rader, MD
University of Pennsylvania School of Medicine
Chairman, Aegerion US Scientific Advisory Board
Dr. Rader is the Cooper-McClure Professor of Medicine and is Professor of Pathology and Pharmacology at the University of Pennsylvania School of Medicine. He is Associate Director of Penn’s Institute for Translational Medicine and Therapeutics and Director of the newly created Translational Research Center. He is also the Director of Preventive Cardiovascular Medicine and Lipid Clinic and the Director of the Lipid-Atherosclerosis Research Unit. Dr. Rader’s basic research laboratory focuses on genetic and pharmacologic regulation of lipoprotein metabolism and atherosclerosis, and he directs a translational research program focusing on human genetics of lipid disorders and atherosclerosis and novel approaches to treatment of dyslipidemia and regression of atherosclerosis. He has a particular interest in HDL metabolism, factors and genes involved in its regulation, the causal nature of the relationship of HDL metabolism to atherosclerosis, and novel approaches to targeting HDL metabolism and reverse cholesterol transport in the treatment, prevention, and regression of atherosclerosis.
Dr Rader received his undergraduate degree from Lehigh University and his medical degree from the Medical College of Pennsylvania. He completed an internship and residency in internal medicine at Yale-New Haven Hospital, followed by a year as a Chief Resident. In 1988 he began a fellowship in lipid metabolism at the Molecular Disease Branch of the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, and was subsequently appointed to a staff scientist position. He was recruited in 1994 to the University of Pennsylvania.
Dr. Rader is a member of the American Society of Clinical Investigation, a past Established Investigator of the American Heart Association, and a recipient of a Burroughs Wellcome Fund Clinical Scientist Award in Translational Research, a Doris Duke Charitable Foundation Distinguished Clinical Scientist Award, and a Bristol Myers Squibb "Freedom to Discover" Unrestricted Cardiovascular Research Grant. Dr. Rader is an editorial board member of Arteriosclerosis Thrombosis and Vascular Biology, American Journal of Physiology (Endocrinology and Metabolism), Circulation, Circulation Research, Journal of Lipid Research, and Trends in Molecular Medicine.
Dr. Rader has authored over 250 peer-reviewed publications, review articles, and book chapters, including chapters on lipoprotein disorders for Harrison’s Principles of Internal Medicine, Topol’s Textbook of Cardiovascular Medicine, and Nelson’s Textbook of Pediatrics. He is a frequently invited speaker nationally and internationally on his basic and translational research in lipoprotein metabolism and atherosclerosis.
John Kastelein
University of Amsterdam
Chairman, Aegerion European Scientific Advisory Board
Dr. John J.P. Kastelein is Chairman of Aegerion’s European Scientific Advisory Board. He is Professor of Medicine and Chairman of the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, where he holds the position of Strategic Chair of Genetics of Cardiovascular Disease. Dr. Kastelein is also President of the Dutch Atherosclerosis Society (DAS) and chairs the National Scientific Committee on Familial Hypercholesterolemia (EHC). He is a member of the Royal Dutch Society for Medicine & Physics, the Council for Basic Science of the American Heart Association and the European Atherosclerosis Society. He is also a Board member of the International Task Force for CHD Prevention and was recently appointed to the Executive Board of the International Atherosclerosis Society (IAS).
Dr. Kastelein’s current research interests are in the etiology, diagnosis, prevention and treatment of hypertriglyceridemia, hypercholesterolemia and low HDL cholesterol; all conditions associated with atherosclerosis and cardiovascular disease. He is an investigator of the Bloodomics and CardioGenics consortia. Besides his scientific research aimed at the etiology of atherogenesis, Dr. Kastelein also serves on a number of executive and steering committees of large intervention studies, including the IDEAL, TNT, CAPTIVATE, ENHANCE, ILLUMINATE, JUPITER, RADIANCE and numerous others.
Dr. Kastelein received his medical degree in Amsterdam in 1980, where he subsequently received specialty training in internal medicine. He was trained in medical genetics, lipidology and molecular biology at the University of British Columbia, Vancouver. Upon his return to the Netherlands, Dr. Kastelein was awarded a doctorate and in 1989 he founded the Lipid Research Clinic at the Academic Medical Centre in Amsterdam, which is currently serving as a tertiary referral center for over 5,000 patients each year, and has become part of the Department of Vascular Medicine.
In 1995, Dr. Kastelein set up a foundation for the active identification of patients with classical familial hypercholesterolemia (FH), for which he currently holds a position on the Board of Directors. In 1997 and 1998 he served a visiting Professorship at the Center for Molecular Medicine and Therapeutics at the University of British Columbia, Vancouver, Canada. During this time, Dr. Kastelein was a co-founder of Xenon Pharmaceuticals, Inc., formerly Xenon Genetics, Inc., a drug discovery company based in Vancouver. Dr. Kastelein was also a co-founder of Amsterdam Molecular Therapeutics, Inc. (AMT), a gene therapy company based on the concept of gene replacement in hereditary lipoprotein disorders. He has published over 580 research papers in peer reviewed journals, including Nature Genetics, Lancet, New England Journal of Medicine, JAMA and Circulation.
James M. McKenney, PHARM.D.
National Clinical Research
James M. McKenney is President and CEO of National Clinical Research in Richmond, Virginia. He is also Professor Emeritus of the School of Pharmacy of Virginia Commonwealth University. Dr. McKenney received his Bachelor of Science degree in pharmacy from the Medical College of Virginia in 1968 and his Doctor of Pharmacy degree in 1972 from Wayne State University of Detroit, Michigan. Dr. McKenney has been a member of the Coordinating and Executive Committees of the National Cholesterol Education Program since its inception in 1985. He was appointed to the prestigious Adult Treatment Panels II and III, to develop guidelines for the evaluation and treatment of hyperlipidemia, in 1990-2 and 1999-2001 respectively. He was one of the first pharmacists in the nation to be recognized with a Fellowship in the American Society of Hospital Pharmacists in 1988. Dr. McKenney was also the first pharmacist awarded Fellowship in the Council on Arteriosclerosis by the American Heart Association in 1993 and was given the Clinical Practice Award for lifetime contributions made to pharmacy practice by the American College of Clinical Pharmacy in 1996. He currently serves on the Board of Directors and is President of the National Lipid Association; for the NLA, he also serves as Chairman of the NLA Task Force on Statin Safety, a year long effort to examine safety issues with statin therapy. Dr. McKenney has published over 140 original-research, peer-reviewed papers and many other articles dealing with hypertension, patient compliance and hyperlipidemia. He has been principal or sub-investigator in over 500 clinical trials with cumulative revenues over 24.5 million dollars. He has given over 1600 presentations to professional, scientific and lay audiences during his career.
Jay D. Horton, MD
University of Texas Southwestern Medical Center
Dr Horton is Associate Professor of Internal Medicine and Molecular Genetics and the Dr. Robert C. and Veronica Atkins Chair in Obesity and Diabetes Research at the University of Texas Southwestern Medical Center. Dr. Horton obtained his B.S. and M.D. degrees from the University of Iowa. He completed his internal medicine residency and fellowship in gastroenterology at UT Southwestern Medical Center. Following the gastroenterology fellowship, he completed a Howard Hughes post-doctoral fellowship in the Department of Molecular Genetics at UT Southwestern Medical Center. Dr. Horton is a former PEW scholar and member of the American Society for Clinical Investigation. He serves as a consulting editor for The Journal of Clinical Investigation and The Journal of Lipid Research. Dr. Horton has also served on multiple scientific review committees including the NIH metabolism and INMP study sections, the American Gastroenterological Association Grant Review Panel. Dr. Horton has a clinical interest in nonalcoholic fatty liver disease. His basic scientific interest is in the molecular regulation of fat and cholesterol metabolism.
Willis C. Maddrey, MD, MACP, FRCP (London)
University of Texas Southwestern Medical Center
Willis C. Maddrey, MD, is Professor of Internal Medicine and is the Executive Vice President for Clinical Affairs at The University of Texas Southwestern Medical Center at Dallas. He is the Adelyn and Edmund M. Hoffman Distinguished Chair in Medical Science at UT Southwestern. Dr. Maddrey received his medical degree from The Johns Hopkins University School of Medicine in Baltimore, Maryland, and completed his residency and Chief Residency on the Osler Medical Service of The Johns Hopkins Hospital. Additional postgraduate work included a fellowship in liver disease with Dr. Gerald Klatskin at Yale University School of Medicine. From 1970 to 1981, Dr. Maddrey directed the liver unit at The Johns Hopkins University School of Medicine where he was Professor of Medicine and Associate Physician in Chief. From 1982 to 1990, he was Magee Professor and Chairman of the Department of Medicine at Jefferson Medical College in Philadelphia. Dr. Maddrey had been at UT Southwestern since 1990. Dr. Maddrey is a member of the American Society for Clinical Investigation and the American Gastroenterological Association. He was President of the American Association for the Study of Liver Diseases in 1981. He is a Master of the American College of Physicians and served as its President in 1992-93 and is a Fellow of the Royal College of Physicians of London. Dr. Maddrey has published extensively in the areas of drug-induced liver disease, chronic viral hepatitis, alcohol-induced liver disease, and primary biliary cirrhosis. He has authored numerous. He has edited or co-edited nine books including Transplantation of the Liver, now in its third edition, and Schiff's Diseases of the Liver, the tenth edition of which was published in November, 2006.
Frank M. Sacks, M.D.
Harvard School of Public Health
Dr. Frank M. Sacks is Professor of Cardiovascular Disease Prevention, Department of Nutrition, Harvard School of Public Health. He is also Professor of Medicine at Harvard Medical School, and a senior attending physician at Brigham and Women’s Hospital where he has had a specialty clinic in hyperlipidemia with the cardiovascular division. He is involved in research and public policy in nutrition, cholesterol disorders, hypertension, and cardiovascular disease.
His research program is a combination of laboratory research on human lipoprotein metabolism, and clinical trials in nutrition and cardiovascular disease. The laboratory research concerns the acute and long term effects of dietary and drug treatments on the function of lipoproteins including VLDL, LDL and HDL in humans; the effects of human lipoproteins on vascular wall cells; and biochemical epidemiology of lipoprotein particle types and CVD. Dr. Sacks was Chair of the Design Committee of the DASH study where the DASH diet was designed, and Chair of the Steering Committee for the DASH-Sodium trial. These multi center National Heart Lung and Blood Institute trials found major beneficial additive effects of low salt and a dietary pattern rich in fruits and vegetables on blood pressure. Dr. Sacks was Co-Chair of the OmniHeart Trial, a multicenter feeding trial that found that a variation of the DASH diet that is higher in protein or unsaturated fat diets further improved blood pressure and lipid risk factors compared to the lower fat DASH-type diet. Dr. Sacks was Principal Investigator of an NIH funded trial on dietary approaches for weight loss and maintenance, the PoundsLost trial. In this trial, 4 diets varying in protein, carbohydrate and fat content were tested in 811 overweight people for 2 years. The diets had the same beneficial effects on weight loss, and all favorably affected risk factors for cardiovascular disease. Dr. Sacks is principal investigator of a new trial that is evaluating the effect of carbohydrate, type and amount, on insulin resistance and cardiovascular risk factors. Dr. Sacks recently published a clinical review on dietary treatment of hypertension in New England Journal of Medicine. This review emphasized that optimizing diet quality, including sodium reduction, can eliminate the age-related rise in blood pressure with age in just 4 weeks, as shown in new analyses in the DASH-Sodium trial.
Dr. Sacks is active in national and international committees and conferences in dietary and drug treatments of dyslipidemia, and nutrition and health guidelines. He is Chair of the American Heart Association Nutrition Committee which advises the AHA on nutrition policy. He is member of the National Cholesterol Education Program Adult Treatment Panel IV, the NIH advisory group that is developing new guidelines for treatment of dyslipidemia. He is a member of the Hypertriglyceridemia Guidelines Committee of the Endocrine Society; and of the National Kidney Foundation KDIGO Committee for Dyslipidemia Guidelines in chronic renal failure. He is a member of the Lifestyle Working Group of the National Heart Lung and Blood Institute Clinical Guidelines for Reducing Cardiovascular Disease. He is a Trustee of the Residual Risk Reduction Institute, Basel, Switzerland. Dr. Sacks is Associate Editor of American Journal of Clinical Nutrition. Dr. Sacks teaches at Harvard School of Public Health as course director for nutritional biochemistry and for scientific writing, and at Brigham & Women’s Hospital on treatment of lipid disorders.
Dr. Sacks has published 175 original research articles and 72 reviews, editorials, and letters.
David E. Cohen, M.D., Ph.D.
Brigham and Women's Hospital, Harvard Medical School and Harvard-MIT Division of Health Sciences and Technology
David E. Cohen, M.D., Ph.D. is currently the Director of Hepatology at Brigham and Women’s Hospital, and Director of the Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology. Dr. Cohen is Robert H. Ebert Associate Professor of Medicine Health Sciences Technology at Harvard Medical School. Dr. Cohen is Master of the Irving M. London Society of HST at Harvard Medical School. He is a faculty member of the graduate program in Biological and Biomedical Sciences at Harvard Medical School and an affiliate of Department of Biological Chemistry and Molecular Pharmacology. Dr. Cohen is a member of the NIH Hepatobiliary Pathophysiology Study Section and recently served as Chair of the American Heart Association Chair Lipoprotein and Lipid Metabolism Study Section, National Chapter. Dr. Cohen’s current research interests include the role of START domain proteins in lipid and lipoprotein metabolism and the impact of obesity on hepatic cholesterol metabolism.
Dr. Cohen received his medical degree from Harvard Medical School in Boston, Massachusetts. He also earned a PhD in physiology and biophysics at Harvard University. He completed his residencies and served as a research fellow in internal medicine at Harvard Medical School and Brigham and Women’s Hospital in Boston. Subsequently, Dr. Cohen completed a clinical fellowship and a research fellowship in gastroenterology at Harvard Medical School and Brigham Women’s Hospital, and then he served as a senior fellow in hepatology at Brigham and Women’s Hospital. In 1995, Dr. Cohen was appointed as Instructor in Medicine at Harvard Medical School. He was promoted to Assistant Professor in 1996. In 1997, he moved to the Albert Einstein College of Medicine, where he held joint appointments in the Departments of Medicine and Biochemistry as a member of the Marion Bessin Liver Research Center. Dr. Cohen returned to Harvard Medical School and Brigham and Women’s Hospital in 2004.
Dr. Cohen is a Fellow of the American College of Physicians and a Fellow of the American Gastroenterological Association. He is also a member of the American Association for the Study of Liver Diseases, the American Society for Clinical Investigation, and the American Society for Biochemistry and Molecular Biology.
Dr. Cohen’s research has been published in the Nature Structural Biology, American Journal of Physiology, Journal of Lipid Research, Journal of Biological Chemistry, Hepatology, Gene, FASEB Journal, FEBS Letters, Biochemical Journal, and Biochemistry. He is also the author of numerous book chapters.
|
|